EXECUTIVE CHAIRMAN & CEO OF MEDICUS TO PARTICIPATE IN A PANEL DISCUSSION The Summit theme “unlocking the $1 Trillion Wealth ...

The FDA agrees that the Company may follow 505(b)(2) regulatory pathway to non-invasively treat basal cell carcinoma (BCC) of the skin using dissolvable Doxorubicin-containing Microneedle arrays ...

Detailed price information for Knight Therapeutics Inc (GUD-T) from The Globe and Mail including charting and trades.

Apotex Inc's ("Apotex") Branded Medicines Division today announced it has entered into a strategic licensing agreement securing exclusive Canadian rights to ...

This article was reviewed by Felix Gussone, MD. What Is Testosterone? As the primary male hormone, or androgen, testosterone ...

MONTREAL, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has relaunched ORGOVYX ® ...

(NASDAQ: MDCX) is a clinical-stage biotech company working on disruptive approaches to cancer and urologic disease. The company’s pipeline is anchored by two high-value programs: SkinJect, a ...

The Company will provide an update on its novel Doxorubicin containing Microneedle Array (D-MNA) treatment to non-invasively treat basal cell carcinoma of the skin (BCC) and development of Teverelix, ...

Alberta's premier says her government might invoke the notwithstanding clause to defend laws affecting transgender people ...

The Company plans to use the proceeds to accelerate the development of Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention (AURr) and high CV ...

The GnRH inhibitor market is shifting toward more convenient, patient-focused treatments, driven by oral therapies such as ORGOVYX and YSELTY. As the pipeline continues to grow and indications expand, ...